SEK1.7 0.0 0.0%
Last Trade - 12/08/20
| Market Cap | £174.3m |
| Enterprise Value | £112.7m |
| Revenue | £12.6m |
| Position in Universe | th / 1831 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.9 | 71.3 | 45.0 | 38.5 | 93.7 | 147.4 | 307 | 40.0 | +56.1% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | June 12, 2001 |
| No. of Shareholders: | 11,464 |
| No. of Employees: | 72 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm (Dual Listing) |
| Shares in Issue | 39,376,096 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Ideon Science Park, LUND, 223 70, Sweden |
| Web | http://www.bioinvent.se/ |
| Phone | +46 46 2868550 |
| Contact | Martin Welschof (President, Chief Executive Officer) |
| Auditors | KPMG AB |
As of 12/08/20, shares in BioInvent International AB are trading at SEK1.7, giving the company a market capitalisation of £174.3m. This share price information is delayed by 15 minutes.
Shares in BioInvent International AB are currently trading at SEK1.7 and the price has moved by 25.17% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioInvent International AB price has moved by -3.01% over the past year.
There are no analysts currently covering BioInvent International AB.
BioInvent International AB is scheduled to issue upcoming financial results on the following dates:
BioInvent International AB does not currently pay a dividend.
BioInvent International AB does not currently pay a dividend.
BioInvent International AB does not currently pay a dividend.
To buy shares in BioInvent International AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in BioInvent International AB are currently trading at SEK1.7, giving the company a market capitalisation of £174.3m.
Here are the trading details for BioInvent International AB:
We were not able to load our ranking data for BioInvent International AB
We were not able to load any forecast data for BioInvent International AB.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioInvent International AB. Over the past six months, the relative strength of its shares against the market has been 5.14%. At the current price of SEK1.7, shares in BioInvent International AB are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for BioInvent International AB.
BioInvent International AB's management team is headed by:
Here are the top five shareholders of BioInvent International AB based on the size of their shareholding:
